Peled, N. Et Al. 2020. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. LUNG CANCER , vol.148 , 48-54.

Peled, N., Gillis, R., KILIÇKAP, S., Froesch, P., Orlov, S., Filippova, E., ... Demirci, U.(2020). GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. LUNG CANCER , vol.148, 48-54.

Peled, Nir Et Al. "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients," LUNG CANCER , vol.148, 48-54, 2020

Peled, Nir Et Al. "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients." LUNG CANCER , vol.148, pp.48-54, 2020

Peled, N. Et Al. (2020) . "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients." LUNG CANCER , vol.148, pp.48-54.

@article{article, author={Nir Peled Et Al. }, title={GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients}, journal={LUNG CANCER}, year=2020, pages={48-54} }